Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Connecting genomic and proteomic signatures of amyloid burden in the brain

  • Puerta, Raquel
  • de Rojas, Itziar
  • García-González, Pablo
  • Olivé-Roig, Claudia
  • Sotolongo-Grau, Oscar
  • García-Sánchez, Ainhoa
  • García-Gutiérrez, Fernando
  • Montrreal, Laura
  • Tartari, Juan Pablo
  • Sanabria, Ángela
  • Pytel, Vanesa
  • Lage, Carmen
  • Quintela, Ines
  • Aguilera, Nuria
  • Rodríguez-Rodríguez, Eloy
  • Alarcón-Martín, Emilio
  • Orellana, Adelina
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Pinol-Ripoll, Gerard
  • López de Munain, Adolfo
  • García-Alberca, José María
  • Royo, José Luis
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis Miguel
  • Corbatón Anchuelo, Arturo
  • Gómez-Garre, Dulcenombre
  • Martínez Larrad, María Teresa
  • Franco-Macias, Emilio
  • Mir, Pablo
  • Medina, Miguel
  • Sánchez-Valle, Raquel
  • Icardo, Oriol
  • Dols-Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Alegret, Montse
  • Valero, Sergi
  • Marquie, Marta
  • Boada, Mercè
  • Juan, Pascual
  • Sánchez Cavazos, José Enrique
  • Cabrera, Alfredo
  • Cano, Amanda
  • Ruiz, Agustín
preprint 42 páginas, 6 figuras, 2 tablas, Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER 'Una manera de hacer Europa') grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia

  • Morató, Xavier
  • Puerta, Raquel
  • Cano, Amanda
  • Orellana, Adelina
  • de Rojas, Itziar
  • Capdevila, María
  • Montrreal, Laura
  • Rosende-Roca, Maitée
  • García-González, Pablo
  • Olivé, Claudia
  • García-Gutiérrez, Fernando
  • Blázquez, Josep
  • Miguel, Andrea
  • Núñez-Llaves, Raúl
  • Pytel, Vanesa
  • Alegret, Montserrat
  • Fernández, María Victoria
  • Marquié, Marta
  • Valero, Sergi
  • Cavazos, Jose Enrique
  • Mañes, Santos
  • Boada, Mercè
  • Cabrera-Socorro, Alfredo
  • Ruiz, Agustín
Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. Moreover, there is debate on whether inflammation has a protective or detrimental effect on disease onset and progression. Indeed, distinct immunological mechanisms may govern protective and damaging effects at early and late stages, respectively. This study aims to (i) identify inflammatory mediators demonstrating robust correlations between peripheral and central nervous system (CNS) compartments by means of plasma and CSF analysis, respectively, and (ii) assess their potential significance in the context of AD and disease progression from mild cognitive impairment (MCI) to dementia. To achieve this, we have examined the inflammatory profile of a well-defined subcohort comprising 485 individuals from the Ace Alzheimer Center Barcelona (ACE). Employing a hierarchical clustering approach, we thoroughly evaluated the intercompartmental correlations of 63 distinct inflammation mediators, quantified in paired CSF and plasma samples, using advanced SOMAscan technology. Of the array of mediators investigated, only six mediators (CRP, IL1RAP, ILRL1, IL6RA, PDGFRB, and YKL-40) exhibited robust correlations between the central and peripheral compartments (proximity scores <400). To strengthen the validity of our findings, these identified mediators were subsequently validated in a second subcohort of individuals from ACE (n = 873). The observed plasma correlations across the entire cohort consistently have a Spearman rho value above 0.51 (n = 1,360, p < 1.77E-93). Of the high CSF-plasma correlated proteins, only soluble IL6RA (sIL6RA) displayed a statistically significant association with the conversion from MCI to dementia. This association remained robust even after applying a stringent Bonferroni correction (Cox proportional hazard ratio [HR] = 1.936 per standard deviation; p = 0.0018). This association retained its significance when accounting for various factors, including CSF amyloid (Aβ42) and Thr181-phosphorylated tau (p-tau) levels, age, sex, baseline Mini-Mental State Examination (MMSE) score, and potential sampling biases identified through principal component analysis (PCA) modeling. Furthermore, our study confirmed the association of both plasma and CSF levels of SPARC-related modular calcium-binding protein 1 (SMOC1) with amyloid and tau accumulation, indicating their role as early surrogate biomarkers for AD pathology. Despite the lack of a statistically significant correlation between SMOC1 levels in CSF and plasma, both acted as independent biomarkers of disease progression (HR > 1.3, p < 0.002). In conclusion, our study unveils that sIL6RA and SMOC1 are associated with MCI progression. The absence of correlations among inflammatory mediators between the central and peripheral compartments appears to be a common pattern, with only a few intriguing exceptions., A. Ruiz received support from the HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Jansen; from the PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from the ADAPTED project, EU/EFPIA Innovative Medicines Initiative Joint Undertaking grant Nº 115975; from the DESCARTES project, German Research Foundation (DFG); and from Fundación Bancaria“La Caixa”, Fundación Echevarne and Grifols S.A. (GR@ACE project). Research funding support for the analyses was granted to the Ace Alzheimer Center Barcelona (X. Morató and M. Boada) by Novo Nordisk. S. Manes received support from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) (grant PID2020-116303RB-I00). The authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Support was also given by Acción Estratégica en Salud, integrated into the Spanish National R +D +I Plan and financed by ISCIII Subdirección General de Evaluaci´ on and Fondo Europeo de Desarrollo Regional (FEDER“Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403, and PI22/00258 and ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under grants CB06/05/ 2004 and CB18/05/00010 is also acknowledged. A. Cano received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and from Fundación ADEY (under the program“Proyectos de Investigacioón en Salud 2023”). I. de Rojas was supported by ISCIII under grant FI20/00215. P. García-Gonz´ alez was supported by the CIBERNED employment plan (CNV-304-PRF-866). S. Valero received support from the TARTAGLIA project, the program of the Spanish Ministry of Science and Innovation R&D Missions in Artificial Intelligence, the Spain Digital 2025 Agenda, and the National Artificial Intelligence Strategy, financed by the European Union through Next Generation EU funds, under grant Nº MIA.2021.M02.0005., Peer reviewed